MedTrace Logo

Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection in Subjects With Acute Drug-induced Liver Injury

NCT02734966 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2016-09-27

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety, effective dosage and treatment of Magnesium Isolycyrrhizinate Injection to cure the acute drug-induced liver injury compared with the Tiopronin Injection.

Conditions

  • Drug-Induced Liver Injury

Interventions

DRUG

Magnesium Isoglycyrrhizinate Injection 100mg OD

Magnesium Isoglycyrrhizinate Injection 100mg OD

DRUG

Magnesium Isoglycyrrhizinate Injection 200mg OD

Magnesium Isoglycyrrhizinate Injection 200mg OD for 4 weeks

DRUG

Tiopronin Injection

Tiopronin Injection 200mg OD

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Minde Zeng, MD · RenJi Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2008-12-31
Completion
2011-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02734966 on ClinicalTrials.gov